CARDIAC INVOLVEMENT IN HYPEREOSINOPHILIC SYNDROME
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Hypereosinophilic syndrome (HES) is a heterogeneous group of conditions that is defined at its core by hypereosinophilia (HE) (blood eosinophil count of >1.5×10(9)/L) and organ damage directly attributable to the HE. Hypereosinophilic syndrome (HES) indicates the presence of HE with organ involvement due to eosinophil action, which can be classified as primary (or neoplastic), secondary (or reactive), and idiopathic. Cardiac involment occurs frequently in all forms of HES ranging from oligosymptomatic cases to fulminant acute myocarditis or chronic restrictive cardiomyopathy (Loeffler endomyocarditis) and is a major cause of morbidity and mortality. The clinical course of the disease can be divided into three phases: 1. Necrotic (acute) phase: Characterized by the infiltration and accumulation of eosinophil cells, leading to cytokine-mediated damage to the endocardium. 2. Thrombotic phase: A layered thrombus forms as a result of tissue factor activation by eosinophil cells accumulating in the myocardium. 3. Fibrotic phase: Myocardial fibrosis and associated wall stiffness. severity of cardiac involvement due to HES depends on both the progression of endocardial fibrosis and associated complications, and the 5-year mortality is estimated to be 30%. The degree of cardiac dysfunction does not directly correlate with the degree of eosinophilia. Echocardiography is routinely performed to assess for cardiac involvement, looking for evidence of left ventricular and/or right ventricular apical obliteration or thrombi or a restrictive cardiomyopathy. Cardiac magnetic resonance imaging is often useful adjuncts to establish the diagnosis but endomyocardial biopsy remains the gold standard. To decrease the degree of eosinophilia, treatment can include corticosteroids and/or imatinib based on the etiology. Anticoagulation, standard heart failure therapy for a restrictive cardiomyopathy and finally cardiac transplantation may be indicated in the treatment algorithm. There are no consensual disease-specific guidelines for treating eosinophil-mediated thrombotic complications and cardiopathy, which should be managed according to classical international recommendations. The aim of this review is to understand the causes and pathophysiology of hypereosinophilia, as well as to summarize the current clinical data and treatment schemes regarding cardiomechanics and cardiac involvement in patient series with HESKeywords: Cardiomyopathy restrictive; Eosinophili; Hypereosinophilic syndrome; Pulmonary eosinophilia
Fields of Study & Subjects
Eosinophilic Disorders and Syndromes
Cardiomyopathy and Myosin Studies
Histiocytic Disorders and Treatments
Publication details
- Journal / source
- Turkiye Klinikleri eBooks
- Pages
- 383–392
- Publication date
- 1 January 2026
- Language
- EN
- Document type
- Book chapter